Lipid metabolism improvement

Lipid metabolism improvement is a physiological outcome and a therapeutic goal rather than a specific molecular target such as a receptor, enzyme, or transporter. It refers to the systemic modulation of pathways involved in the synthesis, transport, and degradation of lipids, including cholesterol and triglycerides, to reduce the risk of cardiovascular events [1]. This metabolic improvement is typically sought in patients with dyslipidemia or atherosclerosis and is achieved by pharmacologically targeting specific proteins like HMG-CoA reductase, PPAR receptors, or PCSK9 [2]. Because the term describes a broad metabolic state or clinical endpoint rather than a distinct biological entity with a specific binding site, it is classified as a biological process [3]. Clinical management of lipid metabolism remains a cornerstone of preventive cardiology, utilizing various drug classes that each contribute to the overall improvement of the patient's lipid profile through different molecular pathways [4].

Other names

Lipid profile improvementModulation of lipid metabolismLipid-lowering effect

Lipid metabolism improvement is achieved through various distinct mechanisms including: 1) Inhibition of HMG-CoA reductase to reduce hepatic cholesterol synthesis; 2) Activation of Peroxisome proliferator-activated receptor alpha (PPAR-alpha) to enhance fatty acid oxidation and increase HDL levels; 3) Inhibition of Proprotein convertase subtilisin/kexin type 9 (PCSK9) to increase LDL receptor recycling; 4) Inhibition of Niemann-Pick C1-like 1 (NPC1L1) to block intestinal cholesterol absorption; and 5) Activation of lipoprotein lipase to lower serum triglycerides.